Q2 Earnings Forecast for CRDF Issued By Zacks Research

Posted by Stanley Muller on May 27th, 2026

Cardiff Oncology, Inc. (NASDAQ:CRDF – Free Report) – Analysts at Zacks Research issued their Q2 2026 earnings estimates for shares of Cardiff Oncology in a research report issued to clients and investors on Tuesday, May 26th. Zacks Research analyst J. Vandermosten forecasts that the company will post earnings of ($0.18) per share for the quarter. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.65) per share. Zacks Research also issued estimates for Cardiff Oncology’s Q3 2026 earnings at ($0.18) EPS and Q4 2026 earnings at ($0.20) EPS.

Cardiff Oncology (NASDAQ:CRDF – Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.09 million. Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%.

CRDF has been the topic of several other reports. Wall Street Zen downgraded Cardiff Oncology from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Piper Sandler cut their price objective on Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Cardiff Oncology in a report on Wednesday, January 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Monday, May 18th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.10.

Get Our Latest Analysis on Cardiff Oncology

Cardiff Oncology Trading Up 9.0%

Shares of Cardiff Oncology stock opened at $1.94 on Wednesday. The stock has a market capitalization of $132.64 million, a price-to-earnings ratio of -2.90 and a beta of 1.36. The firm’s 50-day moving average price is $1.70 and its two-hundred day moving average price is $2.06. Cardiff Oncology has a 1-year low of $1.48 and a 1-year high of $4.56.

Institutional Investors Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Laurion Capital Management LP boosted its holdings in Cardiff Oncology by 7.3% in the fourth quarter. Laurion Capital Management LP now owns 2,646,738 shares of the company’s stock valued at $7,437,000 after acquiring an additional 180,866 shares during the last quarter. Acorn Capital Advisors LLC raised its holdings in Cardiff Oncology by 39.3% during the 3rd quarter. Acorn Capital Advisors LLC now owns 1,962,084 shares of the company’s stock worth $4,042,000 after purchasing an additional 553,317 shares during the last quarter. Geode Capital Management LLC lifted its position in Cardiff Oncology by 7.5% during the 2nd quarter. Geode Capital Management LLC now owns 1,498,838 shares of the company’s stock valued at $4,723,000 after purchasing an additional 104,409 shares during the period. Franklin Resources Inc. bought a new position in shares of Cardiff Oncology in the 4th quarter valued at about $3,388,000. Finally, State Street Corp boosted its stake in shares of Cardiff Oncology by 4.0% in the 4th quarter. State Street Corp now owns 1,191,647 shares of the company’s stock valued at $3,349,000 after purchasing an additional 45,288 shares during the last quarter. Institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

(Get Free Report)

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.